La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

AnGes Salute del bilancio

Salute finanziaria criteri di controllo 6/6

AnGes ha un patrimonio netto totale di ¥25.5B e un debito totale di ¥0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente ¥27.7B e ¥2.2B.

Informazioni chiave

Rapporto debito/patrimonio netto

JP¥0

Debito

Indice di copertura degli interessi	n/a
Contanti	JP¥1.82b
Patrimonio netto	JP¥25.48b
Totale passività	JP¥2.20b
Totale attività	JP¥27.68b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥3.6B ) di 4563 superano le sue passività a breve termine ( ¥1.9B ).

Passività a lungo termine: Le attività a breve termine di 4563 ( ¥3.6B ) superano le sue passività a lungo termine ( ¥271.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 4563 è esente da debiti.

Riduzione del debito: 4563 non ha avuto debiti negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 4563 ha una liquidità sufficiente per 2 mesi in base all'ultimo reportfree cash flow, ma da allora ha raccolto ulteriori capitali.

Previsione Cash Runway: Si prevede che 4563 disponga di liquidità sufficiente per 2 mesi in base al flusso di cassa libero estimates, ma da allora ha raccolto capitale aggiuntivo.

AnGes Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings released: JP¥7.54 loss per share (vs JP¥10.25 loss in 2Q 2023)

New minor risk - Share price stability

AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024

First quarter 2024 earnings released: JP¥9.14 loss per share (vs JP¥15.91 loss in 1Q 2023)

AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024

AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald Europe

New major risk - Share price stability

Full year 2023 earnings released: JP¥37.17 loss per share (vs JP¥94.29 loss in FY 2022)

AnGes, Inc., Annual General Meeting, Mar 28, 2024

Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

New minor risk - Market cap size

AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study

Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study

Third quarter 2023 earnings released: EPS: JP¥0.17 (vs JP¥18.09 loss in 3Q 2022)

Second quarter 2023 earnings released: JP¥10.25 loss per share (vs JP¥29.31 loss in 2Q 2022)

AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd.

New major risk - Share price stability

AnGes, Inc. announced that it expects to receive ¥8.481467 million in funding

AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: JP¥15.91 loss per share (vs JP¥19.19 loss in 1Q 2022)

Full year 2022 earnings released: JP¥94.29 loss per share (vs JP¥92.85 loss in FY 2021)

AnGes, Inc., Annual General Meeting, Mar 30, 2023

AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023

Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)

No independent directors

Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)

AnGes, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: JP¥29.31 loss per share (vs JP¥27.72 loss in 2Q 2021)

AnGes, Inc. to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings released: JP¥19.19 loss per share (vs JP¥24.82 loss in 1Q 2021)

No independent directors

AnGes, Inc. to Report Q1, 2022 Results on May 10, 2022

AnGes, Inc., Annual General Meeting, Mar 30, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: JP¥29.39 loss per share (vs JP¥10.39 loss in 3Q 2020)

Second quarter 2021 earnings released: JP¥27.72 loss per share (vs JP¥8.06 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥24.82 loss per share (vs JP¥8.55 loss in 1Q 2020)

Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)

AnGes, Inc. announced that it has received ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm

AnGes, Inc. announced that it expects to receive ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm

New 90-day low: JP¥1,156

AnGes, Inc., Annual General Meeting, Mar 30, 2021

Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)

AnGes, Inc. to Report Fiscal Year 2020 Results on Feb 15, 2021

AnGes, Inc. (TSE:4563) completed the acquisition of Emendo Bio, Inc. from Orbimed Israel Partners II, L.P., OrbiMed Private Investments VI, LP, managed by OrbiMed Advisors LLC, Takeda Ventures, Inc. and others.

AnGes, Inc. and Er-Kim Enter into an Agreement for the Commercialization of Collategene® in Turkey

AnGes, Inc. to Report Q3, 2020 Results on Oct 26, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane